Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
499.74
-9.01 (-1.77%)
At close: Oct 16, 2026, 4:00 PM EDT
502.00
+2.26 (0.45%)
After-hours: Oct 16, 2026, 7:30 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 32 analysts polled by S&P Global, Vertex Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $571.46. The average 1-year stock price forecast is 14.35% higher than the current stock price, while the lowest is $350 (-29.96%) and the highest is $667 (+33.47%).
Price Target: $571.46 (+14.35%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 21 | 21 | 19 | 19 | 20 | 20 |
| Buy | 6 | 6 | 4 | 4 | 6 | 6 |
| Hold | 5 | 4 | 4 | 4 | 4 | 5 |
| Sell | 0 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 33 | 33 | 29 | 29 | 32 | 32 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $667 | Buy | Maintains | $667 | +33.47% | Oct 15, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $550 | Buy | Maintains | $550 | +10.06% | Oct 15, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $600 | Buy | Maintains | $600 | +20.06% | Oct 12, 2026 |
| Citi | Citi | Buy Maintains $575 → $585 | Buy | Maintains | $575 → $585 | +17.06% | Oct 12, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $570 → $576 | Buy | Maintains | $570 → $576 | +15.26% | Oct 8, 2026 |
Financial Forecast
Revenue This Year
13.27B
from 12.00B
Increased by 10.54%
Revenue Next Year
14.56B
from 13.27B
Increased by 9.74%
EPS This Year
17.85
from 18.40
Decreased by -2.99%
EPS Next Year
20.50
from 17.85
Increased by 14.84%
EPS and Forward PE are based on non-GAAP adjusted numbers.